Abstract
Enteropathy-associated T cell lymphoma (EATL) is a rare entity associated with coeliac disease, with a poor prognosis due to perforation and gastro-intestinal bleeding during treatment, and a high relapse risk. Six patients were treated with two cycles of IVE (ifosphamide, etoposide, epirubicin), followed by two cycles of high-dose methotrexate (3 g/m(2)) with folinic acid rescue and a BEAM (carmustine, etoposide, cytarabine, melphalan) autograft. Enteral feeding was given throughout treatment. Four patients remain alive in complete remission at 1.83-4.32 years; two have relapsed. Given the historically poor outcome in these patients, this regimen appears very promising in the treatment of EATL.
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Carmustine / administration & dosage
-
Celiac Disease / complications*
-
Celiac Disease / immunology
-
Celiac Disease / therapy
-
Combined Modality Therapy
-
Cytarabine / administration & dosage
-
Enteral Nutrition
-
Epirubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Granulocyte Colony-Stimulating Factor / therapeutic use
-
Humans
-
Ifosfamide / administration & dosage
-
Immunosuppressive Agents / therapeutic use
-
Lymphoma, T-Cell, Peripheral / complications*
-
Lymphoma, T-Cell, Peripheral / therapy*
-
Male
-
Melphalan / administration & dosage
-
Methotrexate / therapeutic use
-
Middle Aged
-
Peripheral Blood Stem Cell Transplantation*
-
Podophyllotoxin / administration & dosage
-
Transplantation Conditioning
-
Transplantation, Autologous
-
Treatment Outcome
Substances
-
Immunosuppressive Agents
-
Cytarabine
-
Granulocyte Colony-Stimulating Factor
-
Epirubicin
-
Etoposide
-
Podophyllotoxin
-
Melphalan
-
Carmustine
-
Ifosfamide
-
Methotrexate
Supplementary concepts
-
BEAM protocol
-
IEV protocol